secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-07-02T23:59:59+00:00
Accession:  0001607062-21-000187
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy
--------------------------------------------------------------------------------

- KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.
- Invention pertains to generating IL-17 antitumor effector cells by inhibiting NR2F6.
- NR2F6 described as an immune checkpoint and cancer stem cell differentiator.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000187/0001607062-21-000187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000187/rgbp070221form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer